MedTrace Logo

Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients

NCT00350662 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2012-11-19

No results posted yet for this study

Summary

Comparison of efficacy and toxicity of the combination treatment of deferiprone and desferrioxamine with the single agent treatment of either drug

Conditions

  • Hemochromatosis

Interventions

DRUG

Deferiprone (L1)

75 mg/kg body weight daily

DRUG

Desferrioxamine

In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly

Sponsors & Collaborators

  • Lipomed

    lead INDUSTRY

Principal Investigators

  • Amal M El-Beshlawy, Prof. Dr. · Pediatric Hospital, Cairo University, Cairo, Egypt

  • Yesim Aydinok, Prof. Dr. · EGE University Medical School Bornova, Izmir, Turkey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31

Countries

  • Egypt
  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00350662 on ClinicalTrials.gov